Up to Rs. 50 lakhs per patient is provided for treatment of rare diseases: Centre
New Delhi, Aug 9 (IANS) Up to Rs. 50 lakhs per patient has been provided for treatment of rare diseases, said Anupriya Singh Patel, Union Minister of State for Health and Family Welfare, in a written reply in the Lok Sabha on Friday. The National Policy for Rare Diseases (NPRD) was launched by the Ministry
New Delhi, Aug 9 (IANS) Up to Rs. 50 lakhs per patient has been provided for treatment of rare diseases, said Anupriya Singh Patel, Union Minister of State for Health and Family Welfare, in a written reply in the Lok Sabha on Friday.
The National Policy for Rare Diseases (NPRD) was launched by the Ministry of Health and Family Welfare in March 2021.
Since then, “a total of 1,118 patients have benefited,” Patel informed.
“The financial support of up to Rs. 50 lakhs per patient is provided for the treatment at the notified centres of excellence (CoEs) for rare diseases,” the minister added.
Based on the recommendation of the Central Technical Committee for Rare Diseases (CTCRD), presently 63 rare diseases are included under NPRD, Patel said.
There are also 12 CoEs, where patients can register themselves to avail the financial assistance.
The CoEs include premier Government tertiary hospitals that come with facilities for the diagnosis, prevention, and treatment of rare diseases.
There are about 7,000 known rare diseases, affecting around 8 per cent of the world’s population. About 75 per cent of rare disease patients happen to be children.
The NPRD identifies and categorises rare diseases into 3 groups: disorders that can be controlled to one-time curative treatment; those that require long-term/lifelong treatment with a relatively lower cost of treatment; and those that need definitive treatment but challenges are to make an optimal patient selection for benefit, very high cost, and lifelong therapy.
“The Ministry of Health and Family Welfare has obtained exemption from the Department of Expenditure on Goods & Services Tax (GST) and Basic Customs Duty on drugs imported for Rare Diseases for individual use and through CoE,” Patel said.
Further, she informed that a National Consortium for Research and Development on Therapeutics for Rare Diseases (NCRDTRD) has also been established to streamline research activities for rare diseases.
–IANS
rvt/
Paris Olympics: CM Mohan Majhi Announces Cash Award for Medal Winning Indian Hockey Team
Next Articleଗୀତା ଉପଦେଶ: ସାତ୍ତ୍ୱିକ କର୍ତ୍ତାଗଣ ମୁକ୍ତସଙ୍ଗ ଅର୍ଥାତ୍ ସେମାନେ ସାଂସାରିକ ବିଷୟରେ ଆସକ୍ତ ହୁଅନ୍ତି ନାହିଁ
Related Articles
New AI tool to revolutionise personalised cancer treatment

ସ୍ୱାସ୍ଥ୍ୟ ଓ ଜୀବନଶୈଳୀNew AI tool to revolutionise personalised cancer treatment
New Delhi: An international team of scientists has developed an artificial intelligence (AI) tool that could revolutionise cancer treatment by mapping cellular diversity within tumours. The innovation tackles tumour heterogeneity in oncology, where varied cell populations cause treatment resistance and recurrence, Xinhua news agency reported. The AAnet AI tool, developed by the Sydney-based Garvan Institute
Covid-19 virus protein triggers immune attack on healthy cells: Study

ସ୍ୱାସ୍ଥ୍ୟ ଓ ଜୀବନଶୈଳୀCovid-19 virus protein triggers immune attack on healthy cells: Study
New Delhi: Amid a fresh wave of Covid-19, Israeli researchers have discovered that a protein from the SARS-CoV-2 virus can cause the immune system to attack healthy cells mistakenly. The study, published in the journal Cell Reports, sheds light on how severe Covid complications may occur and suggests new ways to prevent immune-driven damage from
Global AI collaboration revolutionises personalised cancer treatment

ସ୍ୱାସ୍ଥ୍ୟ ଓ ଜୀବନଶୈଳୀGlobal AI collaboration revolutionises personalised cancer treatment
New Delhi: An international team of scientists has unveiled an artificial intelligence (AI) technique that securely analyses global cancer samples, paving the way for more personalised and privacy-protected cancer treatments. This innovative approach promises to accelerate personalised cancer treatment by enabling clinicians to match therapies to individual patients better, Xinhua news agency reported. The study
